DNA Script to contribute to DARPA's mobile vaccine manufacturing platform

By The Science Advisory Board staff writers

March 2, 2021 -- DNA Script has been selected by GE Research to join a collaboration to develop a rapid response, mobile medical manufacturing platform to enable on-demand production of nucleic acid-based vaccines and therapies. The project is part of a Defense Advanced Research Projects Agency (DARPA) program.

The five-year project, totaling $41 million, was awarded as part of DARPA's Nucleic Acids On-Demand World-Wide (NOW) program. DNA Script will receive up to $9.35 million as part of the agreement.

The collaboration aims to create a platform that can produce thousands of ready-to-use vaccine doses at sites of need in fewer than three days. The platform will use DNA Script's enzymatic DNA platform to fuel GE's industrial-scale, nucleic acid amplification production capability. DNA Script's Syntax enzymatic DNA synthesis (EDS) system prints high quality nucleic acids in a compact benchtop instrument without the need for toxic solvents or special conditions that are part of traditional nucleic acid synthesis procedures.

The platform will be used to better prepare deployed forces against biothreat attacks and emerging infectious diseases, as well as for humanitarian operations.

Moderna secures $56M for mobile vaccine manufacturing
Moderna has received $56 million from the Defense Advanced Research Projects Agency to fund manufacturing of nucleic acid vaccines and therapeutics.
CRB introduces multimodal facility to support cell & gene therapy clients
CRB has created SlateXpace, a multimodal manufacturing facility solution to support complex therapeutic product pipelines.

Copyright © 2021 scienceboard.net

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter